Description:
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of
multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to
polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid
leukemia (AML).
Title
- Brief Title: A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia
- Official Title: An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Clinical Trial IDs
- ORG STUDY ID:
LNK-1002-01
- SECONDARY ID:
IND 153144
- NCT ID:
NCT04896112
Conditions
- Acute Myeloid Leukemia
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
Drug | Synonyms | Arms |
---|
LNK01002 | LNK-1000318 | Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg |
Purpose
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of
multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to
polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid
leukemia (AML).
Detailed Description
This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in
patients with myelofibrosis (MF). The study consists of two periods: the dose escalation,
main period and a dose expansion period. In the dose escalation period, successive cohorts of
patients with MF will be enrolled to establish the maximum tolerated dose. In the dose
expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML
patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and
patients with primary MF or PV/ET-MF.
The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical
activity of LNK01002 in patients with myelofibrosis/AML will be evaluated.
Trial Arms
Name | Type | Description | Interventions |
---|
Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg | Experimental | Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg | Experimental | LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 45 mg | Experimental | LNK01002 45 mg BID, followed by a 3-day observation period then 45 mg BID in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg | Experimental | LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 80 mg | Experimental | LNK01002 80 mg BID, followed by a 3-day observation period then 80 mg BID in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg | Experimental | LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles | |
Patients with Acute Myeloid Leukemia With Mutant FLT3 | Experimental | LNK01002 at the RP2D dose in 28-day treatment cycles | |
Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3 | Experimental | LNK01002 at the RP2D dose in 28-day treatment cycles | |
Patients with Primary or Secondary Myelofibrosis | Experimental | LNK01002 at the RP2D dose in 28-day treatment cycles | |
Eligibility Criteria
Inclusion Criteria:
1. Age: 18 years old or older, male or female.
2. Patients must have histologically or cytologically confirmed tumors of the following
types.
3. Dose Escalation Phase: Patients with PMF, PV/ET-MF
1. Intermediate or high-risk primary myelofibrosis, post-polycythemia vera
myelofibrosis, or post-essential thrombocythaemia myelofibrosis which failed
standard treatment.
2. Symptomatic splenomegaly
3. Not undergone splenectomy or splenic radiation therapy within 6 months prior to
screening.
4. Dose expansion phase: Patients with PMF, PV/ET-MF who relapsed or are intolerant to
standard treatment, and relapsed/refractory AML
5. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration
6. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug
administration
7. Women of childbearing potential negative pregnancy test at screening. Female patients
of childbearing potential, or male patients and their partners should agree to
effective contraception from signing ICF until 6 months after the last dose of study
drug.
Exclusion Criteria:
Patients who meet any of the following exclusion criteria will be excluded from the
clinical study:
1. Allergic to any component of LNK01002.
2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN)
reference range, except patients diagnosed as Gilbert's disease
3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by
leukemia, which are excluded if higher than 5 times the ULN
4. Glomerular filtration rate or estimated creatinine clearance < 50 mL/min according to
the Cockcroft-Gault formula;
5. Serum amylase or lipase levels higher than the ULN and considered clinically
significant
6. International normalized ratio (INR) or partial activated prothrombin time (aPTT)
above 1.5 times the ULN reference range
7. Known history of clinically significant liver disease, including viral or other
hepatitis:
a) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative
polymerase chain reaction (PCR)
8. Known human immunodeficiency virus (HIV) infection;
9. Clinically significant cardiovascular diseases, including acute myocardial infarction,
unstable angina, coronary artery bypass surgery within 6 months before enrollment,
congestive heart failure with New York Heart Association (NYHA) classification of III
or above, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled
hypertension, cardiac arrhythmia;
10. Patients with history or presence of clinically relevant non-malignant CNS disease
requiring treatment
11. Patients who have received systemic antineoplastic therapy or radiotherapy within 2
weeks prior to start of study treatment:
12. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60
days prior to the start of study treatment, or are receiving immunosuppressive therapy
after HSCT at screening, or have graft-versus-host disease (GVHD) requiring drug
control:
13. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start
of study treatment;
14. Received CYP3A substrates, CYP2B6 substrates, CYP2C substrates, OATP1B3 substrates,
UGT1A1 inhibitors, or UGT1A3 inhibitors less than one week or 5 half-lives (whichever
is longer) prior to the start of study treatment;
15. Uncontrolled, active infections requiring intravenous antibiotic treatment;
Maximum Eligible Age: | 99 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Assessing the safety and tolerability of LNK01002 in patients with myelofibrosis |
Time Frame: | 31 days |
Safety Issue: | |
Description: | Assessed by monitoring the frequency, duration and severity of adverse events and serious adverse events. |
Secondary Outcome Measures
Measure: | Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Measure: | Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV-MF or ET-MF patients |
Time Frame: | Day 1, Day 2, and Day 15 |
Safety Issue: | |
Description: | Measurement will be using extensive PK sampling |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Lynk Pharmaceuticals Co., Ltd |
Trial Keywords
- Acute Myeloid Leukemia
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Myeloid malignancies
- Myelofibrosis
Last Updated
June 9, 2021